Enhanced Resistance of Mice to Infection with Bacteria following Pre-treatment with Corynebacterium parvum

Adlam, C.; Broughton, E.S.; Scott, Marcia S.

doi:10.1038/newbio235219a0

Cited by 87 publications

(28 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent demonstration in mice of regression of Lewis lung carcinoma metastases following parenteral administration of C. parvrum (Milas et al, 1974), has prompted clinical trials of immunotherapy with C. parrurn in metastatic human cancer (Band et al, 1975;Reed et al, 1975).…”

Section: Patientsmentioning

confidence: 99%

Hepatitis B surface antigen produced by a human hepatoma cell line

Macnab¹,

Alexander²,

Lecatsas³

et al. 1976

Br J Cancer

293

125

View full text Add to dashboard Cite

Summary.-Serum complement levels were assayed in 26 patients with disseminated cancer, who received immunotherapy with infusion of C. parvum. Complement activation, indicated by the consumption of C3 or C4 or both, was found in 46°' of the patients.Serum samples showed direct correlation between decreased C3 and conversion of C3 proactivator, whereas such conversion did not occur when C4 alone was decreased. It is concluded that the bypass (properdin) pathway was activated in patients in whom C3 consumption was detected, while the classical (Cl) pathway was activated in the patients with C4 consumption unaccompanied by C3 decrease. Direct correlation was observed between delayed cutaneous hypersensitivity reactions to recall antigens and the incidence of C. parvum-associated complement activation.

show abstract

Section: Patientsmentioning

confidence: 99%

Hepatitis B surface antigen produced by a human hepatoma cell line

Macnab¹,

Alexander²,

Lecatsas³

et al. 1976

Br J Cancer

293

125

View full text Add to dashboard Cite

show abstract

“…A number of associated effects such as adjuvant activity (Neveu, Branellec and Biozzi, 1964;Biozzi et al, 1966) and increased resistance to bacterial (Adlam, Broughton and Scott, 1972) and protozoal (Nussenzweig, 1967) infection, have since been reported. The inhibitory effect of C. parvum pre-treatment on the growth of a range of experimental mouse tumours (Sarcoma J, Ehrlich ascites, a spontaneous mammary carcinoma, a methylcholanthrene-induced sarcoma and the AKR leukaemia) has been described (Halpern et al, 1966;Woodruff and Boak, 1966;Lamensans et al, 1968).…”

mentioning

confidence: 99%

Biological Effects of Corynebacterium Parvum. III. amplification of resistance and impairment of Active Immunity to Murine Tumours

Smith¹,

Scott²

1972

Br J Cancer

View full text Add to dashboard Cite

The effect of pre-treatment with Corynebacterium parvum on the growth in vivo of a range of experimental mouse tumours with differing characteristics has been investigated. Varying degrees of protection were observed which were generally greater with the more immunogenic tumours. Administration of C. parvum 7 days before immunization with irradiated tumour cells diminished the protective effect which could be obtained by immunization alone. The possible basis for these seemingly conflicting influences is considered.

show abstract

“…It has been reported that a host's resistance to bacterial infection can be increased by pretreatment with bacterial whole cells, with cell wall skeletons, and with bacterial extract(s), e.g., cord factor (43) and phospholipid (20) derived from various species of microorganisms, such as Mycobacterium (7,9,17,18,45), Listeria (10), and Corynebacterium (3,24).…”

mentioning

confidence: 99%

Stimulation of Nonspecific Host Resistance to Infection Induced by Muramyldipeptides

Matsumoto

Ogawa

Nagase

et al. 1981

Microbiology and Immunology

View full text Add to dashboard Cite

The effect of muramyldipeptide (MDP), N-acetylmuramyl-L-alanyl-Disoglutamine [MDP(Ala)], and its analogs on bacterial infection was studied using the experimental model of sepsis infection in mice. Injection of MDP(Ala) gave mice definitive protection against E. coli infection, but only partial protection against P. aeruginosa or K. pneumoniae infection. Several factors influencing the protective activity of MDP(Ala) on E. coli infection were studied, and it was demonstrated that the activity was induced by various routes of administration of MDP(Ala), including the oral route, and was markedly influenced by the bacterial inoculum size. It was also shown that the effective dose of MDP(Ala) was 100 flg per mouse for intraperitoneal, intravenous or subcutaneous injections and 1,000 flg per mouse when administered orally. Furthermore, the optimal interval between MDP-treatment and infection was 24 hr when the treatment was carried out before infection. Clearance of bacterial cells in blood was observed after E. coli infection in mice treated with MDP(Ala).The efficacy of MDP(Ala) and two analogs, N-acetylmuramyl-L-valyl-Disoglutamine [MDP(Val)] and N-acetylmuramyl-L-seryl-D-isoglutamine [MDP (Ser)], was evaluated for the E. coli infection; MDP(Val) was proven to be slightly less active than MDP(Ala), and MDP(Ser) to be the least effective, although MDP(Val) or MDP(Ser) was reported to have higher adjuvanticity than MDP (Ala) for the development of delayed-type hypersensitivity.

show abstract

Enhanced Resistance of Mice to Infection with Bacteria following Pre-treatment with Corynebacterium parvum

Cited by 87 publications

References 4 publications

Hepatitis B surface antigen produced by a human hepatoma cell line

Hepatitis B surface antigen produced by a human hepatoma cell line

Biological Effects of Corynebacterium Parvum. III. amplification of resistance and impairment of Active Immunity to Murine Tumours

Stimulation of Nonspecific Host Resistance to Infection Induced by Muramyldipeptides

Contact Info

Product

Resources

About